Study design of J-ELD AF: A multicenter prospective cohort study to investigate the efficacy and safety of apixaban in Japanese elderly patients

Journal of cardiology
Masaharu AkaoJ-ELD AF Investigators

Abstract

Apixaban, one of the non-vitamin K antagonist oral anticoagulants, was reported to be effective and safe in stroke prevention in patients with atrial fibrillation (AF) based on the global randomized clinical trial, but data are limited on the efficacy and safety of apixaban in Japanese elderly patients. The J-ELD AF Registry is a large-scale, contemporary observational study, continuously and prospectively registering elderly Japanese patients with AF aged 75 years or older who are currently taking apixaban or the elderly who are to receive apixaban in daily clinical practice, and accumulating the outcomes during one-year follow-up period. In addition to standard baseline characteristics, prothrombin time and anti-Xa activity will be measured to investigate the biomarker characteristics. The primary efficacy endpoints will be stroke and systemic embolism, and the primary safety endpoint will be major bleeding requiring hospitalization. The secondary endpoints in this study will be all-cause death, cardiovascular death, acute myocardial infarction, and the composite of stroke/systemic embolism, cardiovascular death, and acute myocardial infarction. As a primary analysis, the primary/secondary endpoints in the enrolled patients w...Continue Reading

References

Aug 1, 1991·Stroke; a Journal of Cerebral Circulation·P A WolfW B Kannel
Sep 12, 2003·The New England Journal of Medicine·Elaine M HylekDaniel E Singer
Nov 1, 2005·Journal of the American College of Cardiology·Albert L WaldoUNKNOWN NABOR Steering Committee
Dec 25, 2009·Circulation. Cardiovascular Quality and Outcomes·Adam J RoseElaine M Hylek
Jul 9, 2010·The American Journal of Medicine·Isla M OgilvieGregory Y H Lip
Feb 12, 2011·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN AVERROES Steering Committee and Investigators
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Feb 14, 2013·Journal of cardiology·Masaharu AkaoUNKNOWN Fushimi AF Registry Investigators
Nov 21, 2013·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN ENGAGE AF-TIMI 48 Investigators
Aug 30, 2014·Journal of cardiology·Takeshi YamashitaUNKNOWN J-RHYTHM Registry Investigators
Feb 15, 2015·Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association·Yuji KatoUNKNOWN Japan Standard Stroke Registry Study Group

❮ Previous
Next ❯

Citations

Jul 21, 2020·International Heart Journal·Takuto AritaTakeshi Yamashita
May 27, 2020·European Journal of Clinical Pharmacology·Shinya SuzukiUNKNOWN J-ELD AF investigators
May 21, 2021·European Journal of Clinical Pharmacology·Shinya SuzukiKen Okumura
Jul 30, 2021·Journal of the American Heart Association·Masato OkadaUNKNOWN J‐ELD AF investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.